Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT04829617
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks), compared to an attention-matched MI-based educational condition, in a randomized trial (NIH Stage II) of 280 patients with New York Heart Association class I-III Heart Failure (HF).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02114, United States
Location status: Recruiting
The investigators are proposing a study that will focus on testing the efficacy of a Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks) in patients with New York Heart Association class I-III HF. The investigators will enroll 280 HF patients, who will take part in a 12-week (with 24 weeks of supplemental text messages) health behavior intervention.
In this project, the investigators hope to do the following:
Participants will undergo two visits (in-person or virtual) during which they will meet with study staff. During the first visit, participants will provide informed consent, answer questionnaires related to psychological and physical health and functioning, have their blood pressure and weight measured, and be asked to monitor their physical activity (using an accelerometer) for one week and medication adherence (using an electronic pill bottle) for two weeks. Participants will be given a urine collection container and asked to provide a urine sample within 4 hours of their first void and before eating breakfast on the day of Visit 2. At the second visit, the urine sample will be collected, and upon confirmation of adequate physical activity and medication adherence data, participants will be randomized to receive the PP-MI intervention or the MI-alone intervention.
Following randomization, all participants will be provided a treatment manual corresponding with their treatment condition, a Fitbit activity tracker, and other treatment materials. The appropriate intervention will be introduced, and the first exercise will be assigned.
Following the second visit, participants in both treatment conditions will complete twelve weekly phone sessions with a study trainer. The phone sessions primarily will include a review of the prior week's session content and a discussion of the rationale and assignment of the next week's exercise/assignment.
Participants in both treatment conditions will receive twice weekly text messages throughout the intervention (Weeks 1-12) and initial follow-up period (Weeks 13-24). During the intervention, these messages will provide information about the PP activity (PP-MI group) and health behavior goal (both groups) discussed that week. During Weeks 13-24, participants in the PP-MI condition will engage with twice weekly, automated, interactive text messages related to PP and health behavior goals. Individuals in the MI-alone group will receive identical messages related to setting health behavior goals as the PP-MI participants and will additionally receive a fixed test message providing education about health behavior adherence.
At Weeks 12, 24, and 48, participants will complete follow-up visits. One week prior to these visits, participants will be mailed an accelerometer and will wear it until their study visit. They will also be sent a container for urine collection, which they will bring to their follow-up visit. During these study visits, participants will be asked to answer questionnaires related to psychological and physical health and functioning, have their blood pressure, weight, and waist circumference measured, will perform a 6 minute walk test, and be asked about cardiovascular outcomes, including hospitalizations, cardiovascular procedures, and cardiac-specific hospitalizations.
Finally, participants will complete phone sessions every 6 months until study end to inquire about hospitalizations and adverse cardiac events.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The 12-week PP-MI intervention focuses on enhancing well-being (through PP) and promoting adherence to physical activity, diet, and medications (through MI). Each week, participants will complete a PP activity and work towards one or more health behavior goals, then complete a phone session with a study trainer. The PP portion of the program will focus on the cultivation of well-being through the performance of easy-to complete activities (e.g., using a strength in a new way) and review of the positive feelings they generate. The MI portion of the program will focus on assisting participants to monitor health behavior adherence, resolve ambivalence to behavior change, set realistic health behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) to encourage completion of PP activities and engagement in health behaviors.
The time- and attention-matched MI-alone intervention focuses on providing education about heart failure (HF) and promoting adherence to physical activity, diet, and medications. Each week, participants will independently complete an activity related to HF education or adherence to a health behavior, then complete a phone session with a study trainer. HF educational topics will include the causes and types of HF, risk factors for cardiovascular disease, methods for monitoring risk factors and symptoms, and the importance of adherence to physical activity, diet, and medications. For each health behavior, study trainers will assist participants to monitor adherence, identify realistic behavior goals, problem-solve barriers, and identify resources to complete behavior change. Finally, participants will receive twice weekly text messages (for 24 weeks) that provide education and encourage engagement in health behaviors.
Time frame: Baseline, 12 Weeks, 24 Weeks, 48 Weeks
Composite score of overall activity (measured by accelerometer in steps/day), sodium excretion (urine sodium in mEq/day), and medication adherence (Medication Event Monitoring System [MEMS] electronic pill bottle). This composite score will be created by calculating z scores for each individual outcome measure and then averaging them for each participant at each time point.
Time frame: Measured for 7 days at baseline, 12 weeks, 24 weeks, and 48 weeks
Physical activity (steps) will be measured via an accelerometer. We will use established accelerometer protocols to measure the mean number of steps taken per day at each time point.
Time frame: Measured for 14 days at baseline, 12 weeks, 24 weeks, and 48 weeks
Medication adherence will be measured using MEMS electronic pill bottles. Participants will receive a MEMS pill bottle at the initial study visit and will be asked to put one cardiac medication (loop diuretic, ACE inhibitor, beta blocker, or aspirin, in that order) in the bottle and then use it throughout the study period (48 weeks). Adherence will be measured by the percentage of appropriate bottle openings over a 2-week period at baseline and the follow-up time points.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Objective sodium intake will be assessed through the measurement of urinary sodium excretion. Participants will provide a sample of their second voiding of the day, and from this sample, urine sodium and urine creatinine will be measured.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Positive affect will be measured using the 10 positive affect items from the PANAS, a well-validated scale used in numerous other behavioral intervention trials.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
The PROMIS 20-item short form (PF-20) will be used to assess physical function.
Time frame: Measured for 7 days at baseline, 12 weeks, 24 weeks, and 48 weeks
MVPA (reported in mean minutes of MVPA/day) will be measured via an accelerometer and recorded in mean minutes/day.
Time frame: Measured for 7 days at baseline, 12 weeks, 24 weeks, and 48 weeks
Sedentary time (mean minutes/day) will be measured via Actigraph accelerometer.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
The Scored Sodium Questionnaire (SSQ) measures the frequency with which individuals have consumed sodium-containing foods in the past month.
Time frame: Measured for 14 days at baseline, 12 weeks, 24 weeks, and 48 weeks
Medication adherence will be measured with the self-report medication adherence tool from the NHLBI Heart and Soul Study.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Optimism will be measured using the LOT-R, a frequently used 6-item instrument that assesses dispositional optimism.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Self-efficacy will be measured using the General Self Efficacy scale (GSE), a validated measure of self-efficacy, given its links to improved adherence.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Depressive symptoms will be measured using the 7-item depression subscale of the HADS.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Anxiety will be measured using the 7-item anxiety subscale of the HADS.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Locus of control will be measured using the 18-item MHLOC.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
The SF-12 will be used to assess health-related quality of life. The SF-12 produces both mental and physical component scores, both of which will be assessed this trial.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
HF-related quality of life will be assessed using the quality of life score from the KCCQ.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
HF symptoms will be measured using the KCCQ total symptom score.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Blood pressure (diastolic and systolic) will be measured by trained nurses using a standardized protocol.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Height and weight (for calculation of body mass index) will be measured by trained nurses.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Waist circumference will be measured by trained nurses and/or dieticians.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Fasting lipids (including LDL and HDL cholesterol) will be measured via blood samples.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Fasting lipids (including triglycerides) will be measured via blood samples.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
Fasting blood glucose levels will be measured via a blood sample.
Time frame: Baseline, 12 weeks, 24 weeks, 48 weeks
A 6-minute walk test will be measured and monitored by trained nurses and/or dieticians to measure functional capacity.
Time frame: Throughout study period (estimated mean duration 28 months)
MACE will be defined as mortality or hospitalization for HF or an acute coronary event (percutaneous coronary intervention or acute coronary syndrome). Data regarding hospitalizations and mortality will be obtained using a three-pronged approach consisting of systematic queries of participants, electronic health record review, and review of records from the National Death Index.
Time frame: Throughout study period (estimated mean duration 28 months)
We will record all-cause hospitalizations for all participants from enrollment to the end of the study data collection period, using systematic queries of participants and review of electronic health records from all Mass General Brigham-affiliated hospitals.
Time frame: Throughout study period (estimated mean duration 28 months)
We will record HF hospitalizations for all participants from enrollment to the end of the study data collection period, using systematic queries of participants and review of electronic health records from all Mass General Brigham-affiliated hospitals.
Time frame: Throughout study period (estimated mean duration 28 months)
We will record vital status for participants from enrollment to the end of study data collection. Data regarding mortality will be obtained using electronic health record review and review of records from the National Death Index.
Contact information is provided by the study sponsor or research team.
Massachusetts General Hospital
Other
A Novel Behavioral Intervention to Promote Adherence in Heart Failure
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03895073
Cardiovascular Diseases, Heart Diseases
Athens, Attica, Greece
View Trial DetailsNCT05934487
Cardiovascular Diseases, Heart Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT07247032
CRT and/or ICD, Cardiovascular Diseases
Paris, France
View Trial DetailsNCT03180320
Cardiovascular Diseases, Heart Diseases
Guangzhou, Guangdong, China
View Trial Details